quinazolines has been researched along with Dermatitis Medicamentosa in 151 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (2.65) | 18.7374 |
| 1990's | 4 (2.65) | 18.2507 |
| 2000's | 71 (47.02) | 29.6817 |
| 2010's | 69 (45.70) | 24.3611 |
| 2020's | 3 (1.99) | 2.80 |
| Authors | Studies |
|---|---|
| Ahn, BC; Cho, BC; Heo, SG; Hong, MH; Kim, HR; Lee, JH; Lim, SM | 1 |
| Chu, CY; Lin, MH; Sheen, YS; Tzeng, WC | 1 |
| Geat, D; Girolomoni, G; Gisondi, P; Lombardo, F; Mattiucci, A; Santo, A | 1 |
| Chen, KL; Cheng, YP; Cho, YT; Chu, CY; Liau, JY; Sheen, YS; Yang, CW | 1 |
| Cáncela-Díez, B; Cuenca-Barrales, C; Galvez-Moreno, M; López-Delgado, D; Ruiz-Villaverde, R | 1 |
| Doan, HQ; Goldstein, J; Hu, MI; Patel, AB; Piha-Paul, SA; Subbiah, V | 1 |
| Acharyya, S; Chakraborty, A; Dasgupta, P; Gangopadhyay, S; Sau, S | 1 |
| Kishi, A; Kiyohara, Y; Yamazaki, N | 1 |
| Chang, JC; Osborne, CK; Parma, J; Pavlick, A; Rimawi, M; Schiff, R; Trivedi, MV | 1 |
| Blackford, AL; Cameron, JL; Choti, MA; De Jesus-Acosta, A; Donehower, RC; Edil, BH; Ellsworth, S; Fan, KY; Hacker-Prietz, A; Herman, JM; Hidalgo, M; Hruban, RH; Laheru, DA; Le, DT; Pawlik, TM; Schulick, RD; Wild, AT; Wolfgang, CL; Wood, LD; Zheng, L | 1 |
| Cheng, PS; Lai, FJ | 1 |
| Chiu, HC; Chiu, HY | 1 |
| Bourra, H; Hassam, B | 1 |
| Agbor-Tarh, D; Aktas, B; Azim, HA; Baselga, J; Bradbury, I; de Azambuja, E; Di Cosimo, S; Dinh, P; Dreosti, L; Eidtmann, H; Greger, JG; Hsieh, RK; Huang, CS; Jackisch, C; Kim, SB; Piccart, M; Smith, I; Vuylsteke, P | 1 |
| Capdevila, J; Filetti, S; Grande, E; Kreissl, MC; Newbold, K; Reinisch, W; Robert, C; Schlumberger, M; Tolstrup, LK; Zamorano, JL | 1 |
| Buck, M; Casado, A; Coens, C; Colombo, N; Curé, H; Despierre, E; Favier, L; Ferrero, A; Green, J; Hall, M; Jimeno, A; Joly, F; Katsaros, D; Lesoin, A; Marth, C; Pujade-Lauraine, E; Ray-Coquard, I; Reed, NS; Reinthaller, A; Steer, CB; Vergote, IB | 1 |
| Alcolea, V; Aparicio, J; Corbellas, M; Diaz Beveridge, R; Fonfría, M; García, J; Giménez, A; Montalar, J; Segura, Á | 1 |
| Rerknimitr, P; Rungtrakulchai, R | 1 |
| Ballester-Sánchez, R; de Unamuno-Bustos, B; Sabater Marco, V; Vilata-Corell, JJ | 1 |
| Au, HJ; Chen, E; Dhani, N; Gill, S; Hedley, D; Kamel-Reid, S; Moore, MJ; Renouf, DJ; Tang, PA; Tran-Thanh, D; Tsao, MS; Wang, L | 1 |
| Abbas, H; Blazeby, JM; Chatterjee, A; Dahle-Smith, A; Davoudianfar, M; Dutton, SJ; Falk, S; Ferry, DR; Fyfe, DW; Gamble, T; Garcia-Alonso, A; Harrison, M; Hubner, RA; Jankowski, J; Julier, P; Kerr, R; Mansoor, W; Peachey, L; Pearson, SR; Petty, RD; Thompson, J | 1 |
| Fontanella, C; Lederer, B; Loibl, S; Nekljudova, V; Untch, M; von Minckwitz, G | 1 |
| Agbor-Tarh, D; Azim, HA; Bradbury, I; de Azambuja, E | 1 |
| Chen, J; Hu, P; Jiang, J; Liu, DY; Tan, FL; Wang, YX; Wu, YW; Zhao, Q; Zheng, X | 1 |
| Akiyama, F; Araki, K; Fukada, I; Horii, R; Ito, Y; Iwase, T; Takahashi, S | 1 |
| Deeken, JF; He, AR; Hwang, J; Marshall, JL; Pishvaian, MJ; Ramos, C; Steadman, K; Subramaniam, D; Urso, CE; Wang, H; Wang, Y | 1 |
| Aparicio, S; Boyle, FM; Chapman, JA; Coleman, RE; Connor, AP; Dent, S; Di Leo, A; Ellard, SL; Gelmon, KA; Huntsman, DG; Kaufman, B; Khasanov, R; Lemieux, J; Manikhas, A; Martin, M; Mukai, H; Nomikos, D; Nusch, A; Parulekar, WR; Pritchard, KI; Rizel, S; Santillana, SL; Schwartzberg, LS; Shepherd, LE; Tjulandin, S; Tonkin, K; Whelan, TJ | 1 |
| Hisada, T; Imai, H; Ishihara, S; Ishizuka, T; Kaira, K; Kuwako, T; Masuda, T; Minato, K; Miura, Y; Mogi, A; Saito, R; Seki, K; Shimizu, K; Sunaga, N; Takise, A; Tomizawa, Y; Utsugi, M; Yamada, M; Yoshino, R | 1 |
| Briley, LP; Byrne, J; Goss, PE; King, KS; Parham, LR; Rappold, E; Spraggs, CF | 1 |
| Chen, KL; Cho, YT; Chu, CY; Lin, CC; Sheen, YS; Tsai, HE; Yang, CW | 1 |
| Dang, C; Friedman, MD; Lacouture, M | 1 |
| Agbor-Tarh, D; Azim, HA; Boyle, F; Bradbury, I; Campbell, C; de Azambuja, E; Dueck, AC; Gomez, H; Huang, Y; Jackisch, C; Lang, I; Perez, EA; Piccart, M; Pritchard, KI; Smith, I; Sonnenblick, A; Untch, M; Wolff, AC; Xu, B | 1 |
| Hattori, Y; Honda, Y; Katsura, S; Manabe, T; Miyachi, Y; Otsuka, A; Terashima, T | 1 |
| Choi, YS; Kong, SH; Seong, JY; Suh, HS | 1 |
| Dunsford, J | 1 |
| Chirinos, RE; Falo, LD; Geskin, LJ; Pomerantz, RG | 1 |
| Adamson, PC; Blaney, SM; Dancey, JE; Gilbertson, RJ; Hamilton, M; Ingle, AM; Jakacki, RI; Krailo, MD; Tersak, J; Voss, SD | 1 |
| Bianchi, F; Neri, I; Patrizi, A | 1 |
| Bajetta, E; Bajetta, R; Buzzoni, R; Di Bartolomeo, M; Dotti, KF; Ferrario, E; Galassi, M; Gevorgyan, A; Mariani, L; Venturino, P | 1 |
| Cholongitas, E; Ioannidou, D; Kokolakis, G | 1 |
| Bangerter, M; Brudler, O; Heinrich, B; Reimer, G | 1 |
| Brown, CW; Campbell, TM | 1 |
| Denzlinger, C; Hass, HG | 1 |
| Lin, SS; Tsai, TH; Yang, HH | 1 |
| Deplanque, G; Deray, G; Dreno, B; Janus, N; Launay-Vacher, V; Mateus, C; Morere, JF; Robert, C; Souquet, PJ | 1 |
| Alkemade, JA; Bovenschen, HJ | 1 |
| Kaley, K; Li, J; Peccerillo, J; Saif, MW | 1 |
| Dunlop, J; Eaby, B; Groves, RW; McPhelim, J; Nicolson, M; Nijjar, R; Steele, J; Thatcher, N; Ukachukwu, I | 1 |
| Beard, C; Kasparian, E; Lin, NU; Morganstern, DE | 1 |
| Afifi, Y; Benomar, S; Bouhllab, J; Boutayeb, S; Errihanni, H; Hamada, S; Hassam, B | 1 |
| Kawana, S; Mitsuishi, T; Motoki, T | 1 |
| Cattaneo, MT; Clementi, E; Ferrario, S; Filipazzi, V; Gambaro, A; Isabella, L; Oteri, A; Piazza, E; Radice, S; Tosca, N | 1 |
| Aractingi, S; Nassar, D; Soutou, B | 1 |
| Pikó, B | 1 |
| Dirschka, T; Hauschild, A; Kroth, J; Wollenberg, A | 1 |
| Barchuk, AS; Ievleva, AG; Imianitov, EN; Ivantsov, AO; Levchenko, EV; Matsko, DE; Mitiushkina, NV; Moiseenko, FV; Moiseenko, VM; Protsenko, SA; Semenov, II; Togo, AV | 1 |
| Araújo, CM; Bezerra, M; Dias, FL; Federico, MH; Ferreira, CG; Fontão, K; Herchenhorn, D; Knust, RE; Martins, RG; Small, I; Viegas, CM | 1 |
| André, MC; Antunes, J; Filipe, P; Pacheco, D; Silva, R; Soares de Almeida, LM | 1 |
| De Jonge, M; Guttman-Yassky, E; Iwata, KK; Krueger, JG; Matthews, L; McCarthy, S; Mita, A; Rowinsky, EK; Verweij, J | 1 |
| Allen, JW; Daw, NC; Furman, WL; Geyer, JR; McGregor, LM; McKibbin, T; Stewart, CF; Tagen, M; Zhao, W | 1 |
| Amitay-Laish, I; David, M; Stemmer, SM | 1 |
| Ahn, JS; Ahn, MJ; Kim, ST; Lee, J; Park, K; Park, YH; Sun, JM | 1 |
| Kowalski, DM; Krawczyk, P; Krzakowski, M; Kucharczyk, T; Milanowski, J; Mlak, R; Wojas-Krawczyk, K | 1 |
| Anadkat, MJ; Hepper, DM; Wu, P | 1 |
| Anadkat, MJ; Balagula, Y; Lacouture, ME; Wu, PA | 1 |
| Balagula, Y; Boone, SL; Lacouture, ME; Luu, M; Patel, J; Rademaker, AW; Sullivan, P | 1 |
| Chanprapaph, K; Pongcharoen, P; Vachiramon, V | 1 |
| Chida, K; Inui, N; Matsuura, S; Nakamura, Y; Ozawa, Y; Shirai, T; Suda, T; Suganuma, H; Toyoshima, M; Yamada, T; Yasuda, K; Yokomura, K | 1 |
| Iwamoto, Y; Katakami, N; Kobayashi, M; Matsui, K; Moriyama, A; Nakagawa, K; Sueoka-Aragane, N; Takada, M; Takeda, K; Yoshioka, H | 1 |
| Correa, PD; Rizwanullah, M; Shrimali, RK | 1 |
| Houwing, RH; Koster, ME; Lips, IM; Vonk, EJ | 1 |
| Budak, K; Pestalozzi, B; Weisshaupt, Ch | 1 |
| Chevreau, C; Cottura, E; Garrido-Stowhas, I; Sibaud, V | 1 |
| Fujita, S; Hata, A; Imai, Y; Ishida, T; Iwasaku, M; Kaji, R; Katakami, N; Kunimasa, K; Tachikawa, R; Tomii, K; Yoshioka, H | 1 |
| Suzuki, Y; Yamamoto, T | 1 |
| Hong, D; Kurzrock, R; Munoz, J | 1 |
| Chachoua, A; Cohen, DE; de Souza, A; Wnorowski, AM | 1 |
| Böker, B; Grohé, C; Lüders, H | 1 |
| Lin, TC; Wu, PY | 1 |
| Damse, A; Lacouture, ME; Rosen, AC; Sherman, E; Wu, S | 1 |
| Nakamura-Wakatsuki, T; Yamamoto, T | 1 |
| Antoniou, C; Katsambas, A; Nikolaou, V; Stratigos, A; Strimpakos, AS; Syrigos, KN | 1 |
| Cheng, YP; Chiu, HY; Jee, SH; Tsai, TF | 1 |
| Abdul Razak, M; Chan, LC; Ong, CK; Tan, WC | 1 |
| Cei, M; Mumoli, N; Vitale, J | 1 |
| Llombart, B; Requena, C; Sanmartín, O | 1 |
| Cho, BC; Lee, JH; Park, JH; Shin, JU | 1 |
| Aneja, M; Berg, SR; Cella, D; Gandhi, M; Hlubocky, FJ; Lacouture, ME; Wagner, LI; Webster, K | 1 |
| Arakawa, K; Fukatsu, M; Kataoka, K; Katsuno, S; Kimura, T; Kondoh, Y; Nakamura, N; Nishiyama, O; Takashima, N; Taniguchi, H; Umemura, T; Watanabe, N | 1 |
| Wang, B; Wang, YN; Zhao, Q | 1 |
| Angelini, F; Bianchetti, S; Gamucci, T; Gemma, D; Grande, R; Mansueto, G; Narducci, F; Sperduti, I; Trombetta, G | 1 |
| Allen, PK; Amini, A; Brown, P; Chang, JY; Chen, SS; Garland, LL; Heymach, JV; Holt, J; Kim, ES; Komaki, R; Liao, Z; McGovern, SL; Munsell, MF; Stea, B; Sulman, E; Unger, W; Wefel, JS; Welsh, JW | 1 |
| Giuliani, J; Marzola, M | 1 |
| Giaccone, G; Kirtschig, G; Scheffer, E; Stoof, TJ; Van Doorn, R | 1 |
| GOERZ, G; IPPEN, H; MEIERS, HG | 1 |
| España, A; Fernandez-Galar, M; López-Picazo, JM | 1 |
| Bessis, D; Fabbro, M; Guillot, B; Jacot, W; Jorda, E; Pujol, JL; Ychou, M | 1 |
| Bañuls, J; Belinchon, I; Blanes, M; Massuti, B; Pascual, JC | 1 |
| Endo, K; Hirabayashi, M; Kurokawa, I | 1 |
| del Valle, ML; Sanz, A | 1 |
| Chosidow, O; Dirschka, T; Elsner, J; Layton, A; Mancini, L; Maughan, T; Morere, JF; Santoro, A; Segaert, S; Sobrero, A; Tabernero, J; Van Cutsem, E | 1 |
| Friberg, G; Kindler, HL; Skoog, L; Vokes, EE; Wade-Oliver, K | 1 |
| Elsner, J; Gutzmer, R; Kapp, A; Werfel, T | 1 |
| Hirashima, T; Kawahara, K; Kawase, I; Kobayashi, M; Matsui, K; Nakamura, Y; Nitta, T; Sasada, S; Takimoto, T | 1 |
| Treudler, R; Zouboulis, CC | 1 |
| Belinchón, I; Pascual, JC; Sivera, F; Yuste, A | 1 |
| Garey, J; Kim, E; Oishi, K; Rhee, J | 1 |
| Acebo, E; Díaz-Pérez, JL; Lasa, O; Martínez de Lagrán, Z; Ratón, JA | 1 |
| Bartralot, R; Bodet, D; García-Patos, V; Heras, C; Mollet, J | 1 |
| Sipples, R | 1 |
| Adams, D; Fernanadez, EM; Seiverling, EV | 1 |
| Mitra, SS; Simcock, R | 1 |
| Aldanondo, I; Fernández-Guarino, M; Garrido, P; González-García, C; Jaén, P; Marquet, A; Pérez-García, B | 1 |
| Cozzani, E; Parodi, A; Santoro, F | 1 |
| Aguilar, A; Aspiroz, C; Cuétara, MS; del Palacio, A; Martin, L | 1 |
| Bruno, R; Eppler, SM; Hamilton, M; Lu, JF; Lum, BL; Rakhit, A; Wolf, J | 1 |
| Calarese, P; Morse, L | 1 |
| Alomar, A; Capdevila, J; García Muret, MP; Marcuello, E; Pallarés, C; Roé, E | 1 |
| Agero, AL; Benvenuto-Andrade, C; Busam, KJ; Dusza, SW; Halpern, AC; Myskowski, P | 1 |
| Hsiao, YP; Shih, HC; Wu, MF; Yang, JH | 1 |
| Aldanondo Fernández de la Mora, I; Fernández-Guarino, M; García-Millán, C; Garrido López, P; Jaén Olasolo, P; Pérez García, B | 1 |
| Bragg, J; Pomeranz, MK | 1 |
| Koldenhof, JJ; Sigurdsson, V; Tjin-A-ton, ML; van Montfrans, C; Voest, EE; Witteveen, PO | 1 |
| Fernández-Guarino, M; Gónzalez-López, C; Olasolo, PJ; Pérez-García, B; Ryan, AM | 1 |
| Fernández-Guarino, M; Garrido López, P; González-García, C; Jaén, P | 1 |
| Al Hammadi, A; Gerstein, W; Tangri, N | 1 |
| Arpin, D; Balme, B; Becuwe, C; Dalle, S; Thomas, L | 1 |
| Nguyen, D; Parr, AL; Steinberg, SM; Tan, AR; Yang, SX | 1 |
| Boelke, E; Budach, W; Enderlein, E; Gerber, PA; Homey, B; Muller, A | 1 |
| Kardaun, SH; van Duinen, KF | 1 |
| Schalock, PC; Zug, KA | 1 |
| Lacouture, ME; Mitchell, EP; Perez-Soler, R; Van Cutsem, E | 1 |
| Blume, JE; Miller, CC | 1 |
| Dietrich, PY; Lübbe, J; Masouyé, I | 1 |
| Ding, K; Pater, J; Seymour, L; Shepherd, FA; Whitehead, M | 1 |
| Chu, CY; Hsiao, CH; Sheen, YS | 1 |
| Epstein, RJ; Leung, TW | 1 |
| Chevreau, C; Delord, JP; Deslandres, M; Sibaud, V | 1 |
| Burgin, S; Heidary, N; Naik, H | 1 |
| Cholongitas, E; Ioannidou, D; Kokolakis, GP | 1 |
| Culkin, A; Eaby, B; Lacouture, ME | 1 |
| Cruz Hernández, JJ; Delgado Fernández, C; Mezquita Pérez, L; Navarro Martín, M; Rodríguez Sánchez, C | 1 |
| Ring, J; Ruzicka, T | 1 |
| Ishikawa, T; Kamide, R; Niimura, M | 1 |
| Demitsu, T; Tomita, Y | 1 |
| Bailey, N; Balmanno, K; Boddy, AV; Calvert, AH; Calvete, JA; Jackson, RC; Lind, M; Rafi, I; Taylor, GA; Webber, S | 1 |
| Guillot, B; Hellier, I; Topard, D; Ychou, M | 1 |
| de Jonge, MJ; de Mulder, PH; Jackman, A; Peters, ME; Planting, AS; Punt, CJ; Smith, R; Sparreboom, A; van De Schraaf, J; Verweij, J | 1 |
| Avery, GS; Brogden, RN; Heel, RC; Speight, TM | 1 |
| Chiba, M; Nagashima, M; Shiohara, T; Tanaka, Y | 1 |
| Kamide, R; Mochizuki, K; Sawada, S; Yamagishi, R | 1 |
19 review(s) available for quinazolines and Dermatitis Medicamentosa
| Article | Year |
|---|---|
Vandetanib photoinduced cutaneous toxicities.
Topics: Aged; Antineoplastic Agents; Dermatitis, Phototoxic; Drug Eruptions; Female; Humans; Male; Middle Aged; Piperidines; Quinazolines | 2019 |
Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer.
Topics: Acneiform Eruptions; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Erlotinib Hydrochloride; Humans; Ichthyosis; Lung Neoplasms; Paronychia; Patient Education as Topic; Pruritus; Quinazolines | 2013 |
Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies.
Topics: Carcinoma, Neuroendocrine; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointestinal Diseases; Humans; Male; Neoplasm Invasiveness; Neoplasm Staging; Patient Selection; Piperidines; Prognosis; Quinazolines; Risk Assessment; Thyroid Neoplasms; Treatment Outcome | 2013 |
Nursing management of epidermal growth factor receptor inhibitor-induced toxicities.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Diarrhea; Drug Eruptions; Drug Monitoring; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Nursing Assessment; Oncology Nursing; Panitumumab; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quinazolines; Severity of Illness Index | 2008 |
[Lapatinib treatment-option in trastuzumab-resistant breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Clinical Trials as Topic; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Eruptions; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lapatinib; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Survival Analysis; Trastuzumab; Treatment Outcome | 2009 |
[Cutaneous side effects of EGFR inhibitors--appearance and management].
Topics: Acneiform Eruptions; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Hair Diseases; Humans; Ichthyosis; Mucositis; Neoplasms; Panitumumab; Paronychia; Protein Kinase Inhibitors; Quinazolines | 2010 |
Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Molecular Targeted Therapy; Panitumumab; Protein Kinase Inhibitors; Quinazolines | 2011 |
[Dermatologic side effects induced by new angiogenesis inhibitors].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Drug Eruptions; Humans; Indazoles; Indoles; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Skin; Sorafenib; Sulfonamides; Sunitinib | 2011 |
Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Eruptions; ErbB Receptors; Female; Humans; Incidence; Lung Neoplasms; Male; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Risk; Severity of Illness Index; Small Cell Lung Carcinoma; Thyroid Neoplasms | 2012 |
The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Forecasting; Humans; Neoplasms; Panitumumab; Protein Kinase Inhibitors; Quinazolines | 2005 |
Management of rash and other toxicities in patients treated with epidermal growth factor receptor-targeted agents.
Topics: Administration, Topical; Antibodies, Monoclonal; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Steroids | 2005 |
Common side effects of anti-EGFR therapy: acneform rash.
Topics: Acneiform Eruptions; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Diarrhea; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Nurse's Role; Oncology Nursing; Patient Education as Topic; Quinazolines; Severity of Illness Index | 2006 |
EGFR-targeted therapy and related skin toxicity.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Female; Humans; Ichthyosis; Middle Aged; Neoplasms; Nurse's Role; Oncology Nursing; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pruritus; Quinazolines; Signal Transduction; Skin Care; Trastuzumab | 2006 |
Dermatologic side effects associated with the epidermal growth factor receptor inhibitors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Drug Eruptions; Epidermal Growth Factor; Erlotinib Hydrochloride; Gefitinib; Humans; Quinazolines | 2006 |
Clinical presentation and pathophysiology of EGFRI dermatologic toxicities.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Hair Diseases; Humans; Lapatinib; Nail Diseases; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Telangiectasis | 2007 |
[Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib | 2008 |
Chemotherapeutic agents and the skin: An update.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cetuximab; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Hair Diseases; Humans; Imatinib Mesylate; Indoles; Mucous Membrane; Nail Diseases; Niacinamide; Phenylurea Compounds; Piperazines; Platinum Compounds; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Skin; Skin Diseases; Sorafenib; Sunitinib; Taxoids | 2008 |
An interdisciplinary consensus on managing skin reactions associated with human epidermal growth factor receptor inhibitors.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benchmarking; Cetuximab; Decision Trees; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Humans; Incidence; Panitumumab; Patient Selection; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quinazolines; Severity of Illness Index | 2008 |
Prazosin: a review of its pharmacological properties and therapeutic efficacy in hypertension.
Topics: Animals; Benzothiadiazines; Blood Pressure; Clinical Trials as Topic; Diuretics; Drug Eruptions; Drug Therapy, Combination; Heart Rate; Humans; Hydralazine; Hypertension; Kidney; Kidney Diseases; Kinetics; Methyldopa; Prazosin; Quinazolines; Renin; Sodium Chloride Symporter Inhibitors; Time Factors | 1977 |
26 trial(s) available for quinazolines and Dermatitis Medicamentosa
| Article | Year |
|---|---|
A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Class I Phosphatidylinositol 3-Kinases; Drug Administration Schedule; Drug Eruptions; Exanthema; Female; Genes, p53; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Stomatitis; Treatment Outcome; Young Adult | 2021 |
Development of acneiform rash does not predict response to lapatinib treatment in patients with breast cancer.
Topics: Acneiform Eruptions; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Drug Eruptions; Female; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2013 |
Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation, Radiation; Drug Eruptions; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Quality of Life; Quinazolines; Radiotherapy, Intensity-Modulated | 2013 |
Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial.
Topics: Adult; Age Factors; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Diarrhea; Drug Administration Schedule; Drug Eruptions; Female; Humans; Incidence; Lapatinib; Logistic Models; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Receptor, ErbB-2; Time Factors; Trastuzumab | 2013 |
Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Ca
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug Administration Schedule; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Europe; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Maintenance Chemotherapy; Middle Aged; Mutation; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum Compounds; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Signal Transduction; Watchful Waiting | 2014 |
A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer.
Topics: Adult; Aged; Deoxycytidine; Dose-Response Relationship, Drug; Drug Eruptions; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2014 |
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Deglutition Disorders; Diarrhea; Disease Progression; Disease-Free Survival; Double-Blind Method; Drug Eruptions; Eating; Esophageal Neoplasms; Fatigue; Female; Gefitinib; Humans; Male; Middle Aged; Pain; Proportional Hazards Models; Quality of Life; Quinazolines; Retreatment | 2014 |
A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Biopsy; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Colorectal Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; ErbB Receptors; Female; Genetic Variation; Genotype; Head and Neck Neoplasms; Humans; Lapatinib; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pharmacogenetics; Quinazolines; Receptor, ErbB-2; Signal Transduction; Treatment Outcome | 2015 |
Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Bridged-Ring Compounds; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Drug Eruptions; Female; Follow-Up Studies; Humans; International Cooperation; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Staging; Patient Selection; Quality of Life; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2015 |
Dermatologic Adverse Events Associated With Use of Adjuvant Lapatinib in Combination With Paclitaxel and Trastuzumab for HER2-Positive Breast Cancer: A Case Series Analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Eruptions; Female; Humans; Lapatinib; Middle Aged; Paclitaxel; Quinazolines; Trastuzumab | 2016 |
Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Drug Eruptions; Exanthema; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Survival Rate; Time Factors; Trastuzumab; Treatment Outcome | 2016 |
Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Neoplasms; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Diarrhea; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Osteosarcoma; Quinazolines; Rhabdomyosarcoma; Temozolomide | 2008 |
Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Eruptions; Erlotinib Hydrochloride; Female; Fever; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mucositis; Neoplasm Metastasis; Neutropenia; Quinazolines | 2009 |
[Effectiveness of gefitinib (Iressa) as first-line therapy for inoperable non-small-cell lung cancer with mutated EGFR gene (phase II study)].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Drug Eruptions; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2010 |
Phase I/II study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brazil; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Confidence Intervals; Drug Administration Schedule; Drug Eruptions; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Hypopharyngeal Neoplasms; Laryngeal Neoplasms; Male; Middle Aged; Oropharyngeal Neoplasms; Quinazolines; Radiotherapy Dosage; Salvage Therapy; Survival Rate | 2010 |
Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Dendrites; Dose-Response Relationship, Drug; Drug Eruptions; Erlotinib Hydrochloride; Exanthema; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Skin | 2010 |
Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutations.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
Phase II study of gefitinib as a first-line therapy in elderly patients with pulmonary adenocarcinoma: West Japan Thoracic Oncology Group Study 0402.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Agents; Diarrhea; Disease-Free Survival; Drug Eruptions; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Smoking; Treatment Outcome | 2011 |
Pre-emptive skin toxicity treatment for anti-EGFR drugs: evaluation of efficacy of skin moisturizers and lymecycline. A phase II study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Colorectal Neoplasms; Drug Eruptions; Emollients; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Lymecycline; Male; Middle Aged; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Skin; Sunscreening Agents; Treatment Outcome | 2013 |
Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cranial Irradiation; Drug Administration Schedule; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Genetic Predisposition to Disease; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Quinazolines; Treatment Outcome | 2013 |
Phase I/II trial of gefitinib and oxaliplatin in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Drug Eruptions; Female; Gefitinib; Humans; Liver Neoplasms; Male; Middle Aged; Nausea; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Rate; Vomiting | 2005 |
Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer.
Topics: Adult; Aged; Algorithms; Analysis of Variance; Area Under Curve; Biotransformation; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Eruptions; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Models, Statistical; Neoplasms; Population; Protein Kinases; Quinazolines | 2006 |
Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatment.
Topics: Acneiform Eruptions; Antineoplastic Agents; Biomarkers; Biopsy; Breast Neoplasms; Carcinoma; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Folliculitis; Gene Expression Profiling; Humans; Ki-67 Antigen; Mitogen-Activated Protein Kinases; Neoplasm Proteins; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Skin | 2008 |
Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3, 4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quinazolone dihydrochloride (AG337) given by 24-hour continuous intravenous infusion
Topics: Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Eruptions; Enzyme Inhibitors; Female; Folic Acid Antagonists; Humans; Infusions, Intravenous; Male; Neoplasms; Quinazolines; Thymidylate Synthase | 1995 |
Phase I and pharmacologic study of oral ZD9331, a novel nonpolyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Marrow; Chromatography, Liquid; Drug Eruptions; Female; Humans; Male; Mass Spectrometry; Middle Aged; Neoplasms; Quinazolines; Thymidylate Synthase; Treatment Outcome | 2002 |
Prazosin: a review of its pharmacological properties and therapeutic efficacy in hypertension.
Topics: Animals; Benzothiadiazines; Blood Pressure; Clinical Trials as Topic; Diuretics; Drug Eruptions; Drug Therapy, Combination; Heart Rate; Humans; Hydralazine; Hypertension; Kidney; Kidney Diseases; Kinetics; Methyldopa; Prazosin; Quinazolines; Renin; Sodium Chloride Symporter Inhibitors; Time Factors | 1977 |
107 other study(ies) available for quinazolines and Dermatitis Medicamentosa
| Article | Year |
|---|---|
Purpuric drug eruptions induced by EGFR tyrosine kinase inhibitors are associated with IQGAP1-mediated increase in vascular permeability.
Topics: Capillary Permeability; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Eruptions; Drug Resistance, Neoplasm; Endothelial Cells; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; ras GTPase-Activating Proteins | 2020 |
Incidence of Adverse Cutaneous Reactions to Epidermal Growth Factor Receptor Inhibitors in Patients with Non-Small-Cell Lung Cancer.
Topics: Acrylamides; Aged; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; ErbB Receptors; Female; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2021 |
Purpuric Drug Eruptions Caused by Epidermal Growth Factor Receptor Inhibitors for Non-Small Cell Lung Cancer: A Clinicopathologic Study of 32 Cases.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Filaggrin Proteins; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Quinazolines | 2017 |
Gray-bluish cutaneous pigmentation and ice-pick scars induced by vandetanib therapy.
Topics: Adult; Antineoplastic Agents; Cicatrix; Color; Drug Eruptions; Facial Dermatoses; Female; Humans; Pigmentation Disorders; Piperidines; Quinazolines | 2018 |
Skin rash as a surrogate marker of clinical response of targeted therapy using gefitinib in advanced or metastatic non-small-cell lung cancer--a retrospective study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Eruptions; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Prognosis; Quinazolines; Retreatment; Retrospective Studies; Sex Factors; Treatment Outcome | 2012 |
"Arrow" sign: a rapid microscopic diagnosis of hair change associated with epidermal growth factor receptor inhibitors.
Topics: Adult; Aged; Antineoplastic Agents; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Hair; Humans; Male; Microscopy; Middle Aged; Quinazolines; Scalp Dermatoses | 2013 |
Scalp pustules in a patient receiving chemotherapy.
Topics: Acneiform Eruptions; Aged; Aged, 80 and over; Biopsy; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Scalp | 2013 |
[Dermal toxicity of erlotinib].
Topics: Drug Eruptions; Erlotinib Hydrochloride; Facial Dermatoses; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2013 |
Management of advanced pancreatic cancer with gemcitabine plus erlotinib: efficacy and safety results in clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Eruptions; Drug Evaluation; Erlotinib Hydrochloride; Female; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2014 |
Erlotinib induced target-like purpura.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Purpura; Quinazolines | 2014 |
Dermatomyositis-like eruption associated with hydroxyurea therapy: a premalignant condition?
Topics: Aged; Dermatomyositis; Diagnosis, Differential; Drug Eruptions; Drug Substitution; Erythema; Female; Humans; Hydroxyurea; Leg Ulcer; Lichenoid Eruptions; Precancerous Conditions; Primary Myelofibrosis; Quinazolines | 2014 |
Does toxicity predict efficacy? Insight into the mechanism of action of lapatinib.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Diarrhea; Drug Eruptions; Female; Humans; Neoadjuvant Therapy; Quinazolines | 2014 |
Reply to C. Fontanella et al.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Diarrhea; Drug Eruptions; Female; Humans; Neoadjuvant Therapy; Quinazolines | 2014 |
Therapeutic effects and adverse drug reactions are affected by icotinib exposure and CYP2C19 and EGFR genotypes in Chinese non-small cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; China; Chromatography, High Pressure Liquid; Crown Ethers; Cytochrome P-450 CYP2C19; Disease-Free Survival; Drug Eruptions; Female; Genes, erbB-1; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Quinazolines; Tandem Mass Spectrometry | 2014 |
Lapatinib-associated mucocutaneous toxicities are clinical predictors of improved progression-free survival in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Eruptions; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Retrospective Studies | 2014 |
First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations.
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Drug Monitoring; ErbB Receptors; Feasibility Studies; Female; Follow-Up Studies; Gefitinib; Humans; Incidence; Japan; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Severity of Illness Index; Survival Analysis | 2015 |
Rash in lapatinib-treated patients is not associated with human leukocyte antigen polymorphisms.
Topics: Alleles; Antineoplastic Agents; DNA; Drug Eruptions; Gene Frequency; Genetic Predisposition to Disease; Genotype; Heterozygote; HLA Antigens; Humans; Lapatinib; Polymorphism, Genetic; Quinazolines | 2015 |
Comparison of Skin Toxic Effects Associated With Gefitinib, Erlotinib, or Afatinib Treatment for Non-Small Cell Lung Cancer.
Topics: Acneiform Eruptions; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Compassionate Use Trials; Cross-Sectional Studies; Drug Eruptions; Erlotinib Hydrochloride; Gefitinib; Humans; Ichthyosis; Lung Neoplasms; Paronychia; Pruritus; Quinazolines; Retrospective Studies | 2016 |
Stevens-Johnson syndrome-like erosive dermatitis possibly related to afatinib.
Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Agents; Drug Eruptions; Female; Humans; Lung Neoplasms; Quinazolines | 2016 |
Necrolytic Migratory Erythema-like Skin Lesion During Gefitinib Treatment: A Rare Cutaneous Adverse Reaction.
Topics: Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Follow-Up Studies; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Necrolytic Migratory Erythema; Protein Kinase Inhibitors; Quinazolines; Rare Diseases; Risk Assessment; Withholding Treatment | 2016 |
Acitretin for treatment of EGFR inhibitor-induced cutaneous toxic effects.
Topics: Acitretin; Administration, Oral; Diagnosis, Differential; Drug Administration Schedule; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Keratolytic Agents; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
Rosaceiform eruption induced by erlotinib.
Topics: Acneiform Eruptions; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2008 |
How important is the pus culture obtained from epithelial growth factor receptor (EGFR) inhibitors' associated rash?
Topics: Antineoplastic Agents; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Male; Middle Aged; Quinazolines; Serratia Infections; Serratia marcescens; Suppuration | 2008 |
[EGFR (epidermal growth factor receptor) inhibitor-associated skin disorders in tumor therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Diagnosis, Differential; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Hair Diseases; Humans; Neoplasms; Quinazolines | 2008 |
Dimorphic cutaneous manifestation of a toxic eruption due to erlotinib therapy.
Topics: Acneiform Eruptions; Aged; Drug Eruptions; Erlotinib Hydrochloride; Folliculitis; Humans; Male; Protein Kinase Inhibitors; Psoriasis; Quinazolines | 2008 |
Long-term treatment of advanced hepatocellular carcinoma with the tyrosine kinase inhibitor erlotinib (Tarceva)--a case report.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Eruptions; Erlotinib Hydrochloride; Fatal Outcome; Follow-Up Studies; Humans; Liver Cirrhosis, Alcoholic; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Palliative Care; Quinazolines; Ultrasonography | 2009 |
Rare cutaneous side-effect of gefitinib masquerading as superficial dermatophytosis.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dermatomycoses; Drug Eruptions; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Perineum; Quinazolines; Scalp Dermatoses; Treatment Outcome | 2009 |
[Description of erlotinib-related skin effects management in France. Results of the PRECEDE study].
Topics: Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Erlotinib Hydrochloride; Female; France; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2009 |
Erlotinib-induced dermatologic side-effects.
Topics: Acneiform Eruptions; Aged; Antineoplastic Agents; Chickenpox; Drug Eruptions; Epidermal Growth Factor; Erlotinib Hydrochloride; Female; Herpesvirus 3, Human; Humans; Protein Kinase Inhibitors; Quinazolines; Virus Activation | 2009 |
Staphylococcus aureus bacteremia related with erlotinib skin toxicity in a patient with pancreatic cancer.
Topics: Bacteremia; Drug Eruptions; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Skin; Staphylococcal Infections; Staphylococcus aureus | 2009 |
Expert consensus on the management of erlotinib-associated cutaneous toxicity in the u.k.
Topics: Drug Eruptions; Erlotinib Hydrochloride; Humans; Protein Kinase Inhibitors; Quinazolines; Survival Rate; United Kingdom | 2009 |
Geographic distribution of lapatinib-induced skin rash: sparing of abdominal skin persists in the transverse rectus abdominis myocutaneous flap.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Drug Eruptions; ErbB Receptors; Female; Humans; Lapatinib; Mammaplasty; Middle Aged; Quinazolines; Surgical Flaps | 2009 |
Hand-foot syndrome and seborrheic dermatitis-like eruption induced by erlotinib.
Topics: Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Dermatitis, Seborrheic; Disease Progression; Drug Eruptions; Erlotinib Hydrochloride; Facial Dermatoses; Follow-Up Studies; Hand Dermatoses; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Syndrome | 2009 |
Erlotinib-induced skin manifestations.
Topics: Adrenal Cortex Hormones; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2009 |
A case of bullous dermatitis induced by erlotinib.
Topics: Adenocarcinoma; Dermatitis; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Skin Diseases, Vesiculobullous | 2009 |
[Cutaneous side effects of EGF receptor inhibitors].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Folliculitis; Gefitinib; Humans; Nail Diseases; Panitumumab; Quinazolines; Skin | 2009 |
Generalized skin drug eruption to natalizumab in a patient with multiple sclerosis.
Topics: Adult; Amitriptyline; Antibodies; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzodiazepines; Carbamazepine; Clorazepate Dipotassium; Drug Eruptions; Eosinophilia; Glatiramer Acetate; Humans; Interferon beta-1a; Interferon-beta; Liver; Male; Multiple Sclerosis; Natalizumab; Peptides; Quinazolines; Thrombocytopenia | 2010 |
Epidermal growth factor receptor polymorphisms and risk for toxicity in paediatric patients treated with gefitinib.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Clinical Trials as Topic; Diarrhea; Drug Eruptions; ErbB Receptors; Exanthema; Gefitinib; Germ-Line Mutation; Humans; Infant; Neoplasms; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Young Adult | 2010 |
Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Coagulase; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Staphylococcal Infections | 2010 |
Prognostic model to predict outcomes in non-small cell lung cancer patients with erlotinib as salvage treatment.
Topics: Aged; Analysis of Variance; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Eruptions; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Models, Statistical; Neoplasm Staging; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2010 |
The applicability of a predictive index for second- and third-line treatment of unselected non-small-cell lung cancer patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Eruptions; Erlotinib Hydrochloride; Exons; Female; Gene Expression Regulation, Neoplastic; Humans; Karnofsky Performance Status; Lipoproteins, HDL; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Sex Factors; Survival Analysis; Time Factors; Weight Loss | 2011 |
Scarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib.
Topics: Aged; Alopecia; Carcinoma, Non-Small-Cell Lung; Cicatrix; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Quinazolines | 2011 |
Higher severity grade of erlotinib-induced rash is associated with lower skin phototype.
Topics: Adult; Aged; Aged, 80 and over; Drug Eruptions; Erlotinib Hydrochloride; Exanthema; Female; Humans; Incidence; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Severity of Illness Index; Skin Pigmentation; United States | 2011 |
Papulopustular eruptions in a 32-year-old woman after lung cancer treatment.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Agents; Dermatologic Agents; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Hydrocortisone; Lung Neoplasms; Metronidazole; Mupirocin; Quinazolines | 2011 |
Valuable lessons from treatment of non-small cell lung cancer with erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.
Topics: Adult; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2008 |
Erlotinib-induced rash spares previously irradiated skin.
Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Dose Fractionation, Radiation; Drug Eruptions; Erlotinib Hydrochloride; Fatal Outcome; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pleural Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiodermatitis; Radiotherapy, Adjuvant; Tomography, X-Ray Computed | 2011 |
[Adverse effects of new oncologic therapies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Cetuximab; Colonic Neoplasms; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Facial Dermatoses; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; Trastuzumab | 2011 |
Erlotinib for pretreated squamous cell carcinoma of the lung in Japanese patients.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking; Survival Analysis | 2011 |
Reactive perforating collagenosis during erlotinib therapy.
Topics: Aged; Collagen Diseases; Diabetes Complications; Drug Eruptions; Erlotinib Hydrochloride; Humans; Male; Protein Kinase Inhibitors; Quinazolines; Skin Diseases | 2012 |
Anticoagulation-induced severe bleeding in a patient receiving bevacizumab therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Eruptions; Drug Interactions; Erlotinib Hydrochloride; Female; Gastrointestinal Hemorrhage; Hematoma; Heparin, Low-Molecular-Weight; Humans; Middle Aged; Neoplasm Staging; Quinazolines; Severity of Illness Index; Venous Thrombosis | 2012 |
The management of EGFR inhibitor adverse events: a case series and treatment paradigm.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Retrospective Studies; Treatment Outcome | 2012 |
[Prognostic relevance of body mass index and rash for patients with metastatic non-small-cell lung cancer under therapy with erlotinib].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Body Height; Body Mass Index; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Drug Eruptions; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sex Factors; Smoking; Statistics as Topic; Survival Analysis | 2012 |
Painful annular pustular drug eruption induced by erlotinib in a patient with non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Pain; Protein Kinase Inhibitors; Quinazolines | 2011 |
Purpuric drug eruption and alopecia induced by erlotinib.
Topics: Adenocarcinoma; Aged; Alopecia; Dermis; Drug Eruptions; Erlotinib Hydrochloride; Humans; Leg; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2012 |
Azithromycin pulses for the treatment of epidermal growth factor receptor inhibitor-related papulopustular eruption: an effective and convenient alternative to tetracyclines.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azithromycin; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Male; Middle Aged; Neoplasms; Panitumumab; Pulse Therapy, Drug; Quinazolines; Retrospective Studies; Time Factors | 2012 |
Erlotinib-induced generalized eczema craquelé and follicular rash sparing the previous radiation field.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Eruptions; Eczema; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
Cutaneous side-effects of epidermal growth factor receptor-tyrosine kinase inhibitor (TKI) in the treatment of lung cancer: description and its management.
Topics: Adenocarcinoma; Adult; Disease Progression; Drug Eruptions; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
Erlotinib-associated dermatological toxicity.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Facial Dermatoses; Female; Humans; Lung Neoplasms; Quinazolines | 2013 |
Acneiform eruptions induced by epidermal growth factor receptor inhibitors: treatment with oral isotretinoin.
Topics: Acneiform Eruptions; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Dermatologic Agents; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Isotretinoin; Male; Quinazolines | 2012 |
Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor.
Topics: Acneiform Eruptions; Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome; Tumor Cells, Cultured | 2012 |
The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Health Status; Humans; Male; Middle Aged; Neoplasms; Qualitative Research; Quality of Life; Quinazolines; Surveys and Questionnaires | 2013 |
Prognosis in patients with non-small cell lung cancer who received erlotinib treatment and subsequent dose reduction due to skin rash.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Comorbidity; Dose-Response Relationship, Drug; Drug Eruptions; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Prevalence; Prognosis; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Treatment Outcome | 2012 |
Spared pre-irradiated area in pustular lesions induced by icotinib showing decreased expressions of CD1a+ langerhans cells and FGFR2.
Topics: Acneiform Eruptions; Adenocarcinoma; Adenocarcinoma of Lung; Antigens, CD1; Antineoplastic Agents; Biopsy; Blister; Chemotherapy, Adjuvant; Crown Ethers; Dose Fractionation, Radiation; Down-Regulation; Drug Eruptions; Enzyme Inhibitors; ErbB Receptors; Face; Folliculitis; Humans; Immunohistochemistry; Ki-67 Antigen; Langerhans Cells; Lung Neoplasms; Male; Middle Aged; Protein-Tyrosine Kinases; Quinazolines; Receptor, Fibroblast Growth Factor, Type 2; Skin; Thoracic Wall | 2013 |
The management of skin toxicity during erlotinib in advanced non-small cell lung cancer: how much does it cost?
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Eruptions; Erlotinib Hydrochloride; Female; Health Care Costs; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2013 |
Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor.
Topics: Acneiform Eruptions; Antineoplastic Agents; Drug Eruptions; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Quinazolines | 2002 |
[HYPERSENSITIVITY TO SULFONAMIDES. CROSS REACTIONS BETWEEN ANTIBACTERIAL SULFONAMIDES AND DIURETICS].
Topics: Acetazolamide; Anti-Bacterial Agents; Anuria; Cross Reactions; Diuretics; Drug Eruptions; Drug Hypersensitivity; Hydrochlorothiazide; Quinazolines; Sulfadimethoxine; Sulfamethoxypyridazine; Sulfonamides; Toxicology | 1964 |
Acneiform lesions secondary to ZD1839, an inhibitor of the epidermal growth factor receptor.
Topics: Acneiform Eruptions; Adenocarcinoma; Antineoplastic Agents; Drug Eruptions; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2004 |
Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours.
Topics: Acneiform Eruptions; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasms; Quinazolines | 2004 |
Trichomegaly following treatment with gefitinib (ZD1839).
Topics: Antineoplastic Agents; Drug Eruptions; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Hair Diseases; Humans; Middle Aged; Quinazolines | 2004 |
Purpuric drug eruption possibly due to gefinitib (Iressa).
Topics: Aged; Antineoplastic Agents; Drug Eruptions; Ecchymosis; Female; Gefitinib; Humans; Purpura; Quinazolines | 2005 |
A man whose scapula was spared a drug-associated rash.
Topics: Antineoplastic Agents; Drug Eruptions; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Peripheral Nervous System Neoplasms; Phrenic Nerve; Protein Kinase Inhibitors; Quinazolines; Scapula; Sebaceous Glands | 2005 |
[Cutaneous side effects of EGF-receptor inhibition and their management].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Diagnosis, Differential; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Statistics as Topic | 2006 |
Gefitinib for previously untreated patients with non-small cell lung cancer (NSCLC)--a retrospective study of 12 patients treated in one institution.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Diarrhea; Drug Eruptions; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Retrospective Studies | 2005 |
Follicular drug eruption induced by gefitinib (ZD 1839, iressa): clinical picture correlates with in vitro data of focal epidermal necrosis after epidermal growth factor inhibition in skin cultures.
Topics: Acneiform Eruptions; Aged; Antineoplastic Agents; Cells, Cultured; Drug Eruptions; ErbB Receptors; Facial Dermatoses; Fatal Outcome; Gefitinib; Humans; Male; Protein-Tyrosine Kinases; Quinazolines; Skin; Stevens-Johnson Syndrome | 2005 |
Severe cutaneous toxicity following treatment with gefitinib (ZD1839).
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Eruptions; ErbB Receptors; Fatal Outcome; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines | 2005 |
[Acneiform eruption from epidermal growth factor receptor inhibitors].
Topics: Acneiform Eruptions; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Quinazolines | 2005 |
[Contribution to acneiform eruptions by epidermal growth factor receptor inhibitors].
Topics: Acneiform Eruptions; Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colonic Neoplasms; Disease Susceptibility; Drug Eruptions; ErbB Receptors; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Proteins; Quinazolines; Staphylococcal Skin Infections; Superinfection | 2006 |
Epidermal growth factor receptor (EGFR) inhibitor associated skin eruption.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anti-Inflammatory Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clindamycin; Drug Eruptions; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Sulfacetamide; Triamcinolone | 2006 |
Erlotinib induced skin rash spares skin in previous radiotherapy field.
Topics: Adenocarcinoma; Back; Brain Neoplasms; Chemotherapy, Adjuvant; Drug Eruptions; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Reoperation; Skin; Thoracic Wall | 2006 |
[Gefitinib-induced perforating dermatosis].
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Eruptions; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Skin Ulcer | 2006 |
Cutaneous adverse effects during therapy with an epidermal growth factor receptor (EGFR) inhibitor.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2006 |
Erlotinib associated with rosacea-like folliculitis and Malassezia sympodialis.
Topics: Aged; Antineoplastic Agents; Dermatomycoses; Drug Eruptions; Erlotinib Hydrochloride; Folliculitis; Humans; Malassezia; Male; Quinazolines; Rosacea | 2006 |
Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2006 |
Gefitinib-induced acute generalized exanthematous pustulosis in two patients with advanced non-small-cell lung cancer.
Topics: Acute Disease; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Skin Diseases, Vesiculobullous | 2006 |
[Treatment of acneiform rash by epidermal growth factor inhibitors with oral tetracyclines].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antineoplastic Agents; Doxycycline; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2006 |
Papulopustular drug eruption due to an epidermal growth factor receptor inhibitors, erlotinib and cetuximab.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Rectal Neoplasms; Rosacea | 2007 |
[Skin eruptions as an adverse reaction to epidermal growth-factor receptor inhibitors].
Topics: Acneiform Eruptions; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma; Cetuximab; Drug Eruptions; ErbB Receptors; Gefitinib; Humans; Kidney Neoplasms; Male; Melanoma; Middle Aged; Paronychia; Protein Kinase Inhibitors; Quinazolines | 2007 |
Necrotizing vasculitis due to gefitinib (Iressa).
Topics: Antineoplastic Agents; Drug Eruptions; Gefitinib; Humans; Male; Middle Aged; Quinazolines; Skin; Vasculitis | 2007 |
[Erlotinib (Tarceva) induced severe exanthema].
Topics: Biopsy; Drug Eruptions; Erlotinib Hydrochloride; Exanthema; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Skin; Time Factors | 2007 |
Epidermal growth factor receptor inhibitor-related folliculitis.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Face; Folliculitis; Humans; Lung Neoplasms; Male; Neck; Protein Kinase Inhibitors; Quinazolines | 2007 |
Exfoliative eruption secondary to gefitinib (ZD1839).
Topics: Aged; Antineoplastic Agents; Drug Eruptions; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2007 |
Radiation-induced prevention of erlotinib-induced skin rash is transient: a new aspect toward the understanding of epidermal growth factor receptor inhibitor associated cutaneous adverse effects.
Topics: Adenocarcinoma; Back; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Drug Eruptions; Epidermal Growth Factor; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Skin | 2007 |
Erlotinib-induced florid acneiform rash complicated by extensive impetiginization.
Topics: Aged; Anti-Bacterial Agents; Diarrhea; Dose-Response Relationship, Drug; Drug Eruptions; Emollients; Erlotinib Hydrochloride; Humans; Male; Middle Aged; Minocycline; Protein Kinase Inhibitors; Pruritus; Quinazolines | 2008 |
Acneiform reaction to erlotinib.
Topics: Acneiform Eruptions; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2007 |
Livedo reticularis with retiform purpura associated with gefitinib (Iressa).
Topics: Aged; Antineoplastic Agents; Drug Eruptions; Gefitinib; Humans; Livedo Reticularis; Male; Prostatic Neoplasms; Purpura; Quinazolines; Skin | 2007 |
Generalized xerotic dermatitis with neutrophilic spongiosis induced by erlotinib (Tarceva).
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Dermatitis; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kidney Neoplasms; Middle Aged; Neutrophils; Protein Kinase Inhibitors; Quinazolines; Skin | 2008 |
Validation of treatment induced specific adverse effect as a predictor of treatment benefit: a case study of NCIC CTG BR21.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Drug Eruptions; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors; Survival Analysis; Time Factors | 2008 |
Severe purpuric xerotic dermatitis associated with gefitinib therapy.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Erythema; Female; Gefitinib; Humans; Leg; Lung Neoplasms; Male; Purpura; Quinazolines | 2008 |
Tumor resensitization to erlotinib following brief substitution of cetuximab.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Bone Neoplasms; Cetuximab; Deoxycytidine; Drug Eruptions; Drug Interactions; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Proteins; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
Painful pustular eruption in the groin and the scrotum induced by erlotinib.
Topics: Aged; Drug Eruptions; Erlotinib Hydrochloride; Genital Diseases, Male; Groin; Humans; Male; Protein Kinase Inhibitors; Quinazolines; Scrotum; Skin Diseases, Vesiculobullous | 2008 |
[Acneiforme rash in woman with pulmonary adenocarcinoma].
Topics: Acneiform Eruptions; Adenocarcinoma; Aged; Drug Eruptions; Erlotinib Hydrochloride; Facial Dermatoses; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
Hypersensitivity to prazosin.
Topics: Aged; Drug Eruptions; Drug Hypersensitivity; Female; Humans; Hypertension; Prazosin; Quinazolines; Urticaria | 1983 |
Photoleukomelanodermatitis (Kobori) induced by afloqualone.
Topics: Aged; Drug Eruptions; Humans; Male; Muscle Relaxants, Central; Photosensitivity Disorders; Pigmentation Disorders; Quinazolines | 1994 |
Fixed drug eruption due to afloqualone: the first reported case.
Topics: Adult; Drug Eruptions; Female; Headache; Humans; Muscle Relaxants, Central; Patch Tests; Quinazolines | 1998 |
[Raltitrexed-induced skin reaction].
Topics: Aged; Antimetabolites, Antineoplastic; Drug Eruptions; Humans; Male; Quinazolines; Thiophenes | 2000 |
Drug-induced, photosensitive, erythema multiforme-like eruption: possible role for cell adhesion molecules in a flare induced by Rhus dermatitis.
Topics: Adult; Antibodies, Monoclonal; Cell Adhesion Molecules; Dermatitis, Toxicodendron; Drug Eruptions; Erythema Multiforme; HLA-DR Antigens; Humans; Intercellular Adhesion Molecule-1; Keratinocytes; Male; Photosensitivity Disorders; Quinazolines; Skin Tests | 1990 |
[Two cases of photosensitive drug eruption induced by afloqualone].
Topics: Aged; Aged, 80 and over; Animals; Drug Eruptions; Guinea Pigs; Humans; Male; Middle Aged; Photosensitivity Disorders; Quinazolines; Skin | 1986 |